David Sinclair (Harvard Professor) Reveals Age-Reversing Science to Look & Feel Younger

What It Covers

Harvard Medical School professor David Sinclair joins Peter Diamandis to deliver a comprehensive update on age-reversal science in 2025, covering epigenetic reprogramming trials entering human testing in January 2026, AI-accelerated drug discovery reducing treatment costs from millions to roughly $100 per monthly course, longevity escape velocity timelines, current personal protocols, and the financial and scientific consequences of federal research funding cuts to Harvard.

Key Questions Answered

• •Epigenetic Reprogramming Timeline: Life Biosciences plans to begin human trials in January 2026, targeting glaucoma and stroke-induced blindness using a single AAV injection combined with a doxycycline trigger. Non-human primate data shows approximately 95% reversal of optic nerve biological age. The on/off system requires only six to eight weeks of gene activation, after which tissues remain younger and can be retreated periodically without permanent genetic alteration.
• •AI-Driven Cost Reduction: Sinclair's lab uses AI to virtually screen trillions of molecules against four epigenetic enzyme targets simultaneously, compressing work that would take hundreds of thousands of years into roughly two months. This has produced candidate molecules costing under $100 for a full monthly course. A holiday-season mouse experiment using an oral cocktail administered Monday, Wednesday, and Friday for four weeks produced measurable biological age reversal across multiple physiological markers.
• •Four-Lever Epigenetic Framework: Age reversal appears to require modulating four specific enzyme pathways that control the epigenome: inhibiting three and activating one. Current published protocols use cocktails of up to six molecules, now narrowed to three, with single-molecule candidates in active testing. Identifying one safe compound that hits all four targets simultaneously would dramatically simplify clinical development and enable a straightforward daily pill regimen within approximately ten years.
• •Cancer and Senescent Cell Reprogramming: Epigenetic reprogramming appears to kill many cancer cell types rather than rejuvenate them. Cancer cells, when reprogrammed, recognize their accumulated DNA damage and trigger self-destruction, while normal cells return to a younger state. Separately, senescent cells — which normally secrete inflammatory signals and can promote cancer — can be reprogrammed back toward functional states, offering a potential alternative to senolytic drugs that simply destroy them.
• •Longevity Protocol Specifics: Sinclair's current regimen includes one gram of NMN daily (shown to double intracellular NAD levels), resveratrol, fisetin, berberine (replacing metformin due to gastrointestinal side effects and muscle-growth concerns), 81mg coated aspirin, vitamin D, vitamin K, EPA/DHA, and spermidine. He follows a 90–95% plant-based diet, limits eating to one or two meals daily, has eliminated alcohol almost entirely, uses infrared sauna regularly, and prioritizes resistance training for muscle preservation.
• •NAD Supplementation Nuance: One gram of NMN roughly doubles intracellular NAD; two grams approximately triples it, with no evidence that exceeding two grams provides additional benefit. The claim that NAD boosters deplete methyl groups and require trimethylglycine supplementation lacks published supporting evidence. NMN purity varies significantly across commercial brands, with some containing bacterial endotoxins. Metro Biotech's pharmaceutical-grade crystalline NMN (MIB-626) is in five active clinical trials covering Alzheimer's disease, kidney function, strength, and endurance outcomes.
• •Immune System Preservation Over Suppression: Rapamycin, despite popularity in longevity circles, showed no measurable effect on epigenetic age in a comparative clinical trial analysis, while caloric restriction and metformin showed positive results. Chronic mTOR inhibition risks suppressing immune surveillance against cancer and latent viruses including CMV, which is now linked to multiple sclerosis and affects the majority of adults. Sinclair limits rapamycin to approximately four pulsed doses per year and monitors immune cell counts and inflammatory cytokines regularly.